Essential Thrombocytosis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2015-10-08
Clinical Trial Update: Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis [Phase 2]
A Phase 2 open-label trial of oral CEP-701 (lestaurtinib) in Polycythemia Vera and Essential Thrombocythemia has completed.